Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...